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Efficacy of species-specific protein 
antibiotics in a murine model of 
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Daniel Walker1
Protein antibiotics, known as bacteriocins, are widely produced by bacteria for intraspecies 
competition. The potency and targeted action of bacteriocins suggests that they could be developed 
into clinically useful antibiotics against highly drug resistant Gram-negative pathogens for which 
there are few therapeutic options. Here we show that Pseudomonas aeruginosa specific bacteriocins, 
known as pyocins, show strong efficacy in a murine model of P. aeruginosa lung infection, with the 
concentration of pyocin S5 required to afford protection from a lethal infection at least 100-fold lower 
than the most commonly used inhaled antibiotic tobramycin. Additionally, pyocins are stable in the 
lung, poorly immunogenic at high concentrations and efficacy is maintained in the presence of pyocin 
specific antibodies after repeated pyocin administration. Bacteriocin encoding genes are frequently 
found in microbial genomes and could therefore offer a ready supply of highly targeted and potent 
antibiotics active against problematic Gram-negative pathogens.
For Gram-negative pathogens such as Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli ther-
apeutic options are often limited. In the case of the opportunistic pathogen P. aeruginosa, resistance to every 
available class of antibiotic has been observed and between 18% and 25% of clinical isolates are multidrug resist-
ant1–4. In addition to inherent and acquired antibiotic resistance mechanisms, the ability of P. aeruginosa to form 
biofilms during chronic infection and the appearance of antibiotic resistant phenotypic variants during prolonged 
antibiotic therapy can render this pathogen essentially untreatable5–7. This is now evident with an increasing 
prevalence of pan-drug resistant P. aeruginosa infections worldwide8. Consequently, there is an urgent need to 
consider alternative strategies for antibiotic development, to bolster a developmental pipeline that in recent dec-
ades has yielded no effective novel small molecule antibiotics against P. aeruginosa and other difficult to treat 
Gram-negative bacteria9–11.
One alternative strategy for the discovery of effective antibiotics is the exploitation of potent narrow-spectrum 
antibiotics produced by many bacteria for intraspecies competition. In P. aeruginosa, K. pneumoniae and E. coli 
these take the form of multi-domain protein antibiotics known as the S-type pyocins, klebicins and colicins 
respectively12–15. These bacteriocins have evolved to efficiently cross the Gram-negative outer membrane through 
the parasitisation of active nutrient uptake pathways, which are an Achilles’ heel for Gram-negative bacteria16–21. 
The pyocins of P. aeruginosa target several different outer membrane receptors involved in uptake of the essential 
nutrient iron and pyocin L1 has also been shown to bind to the common polysaccharide antigen (CPA), which is 
the major surface antigen produced by P. aeruginosa when growing in the lungs of CF patients14,22–24. The cellular 
targets of bacteriocins are highly conserved, with cytotoxic activity most commonly taking the form of a nuclease 
activity targeting DNA, rRNA or tRNA, a pore-forming activity targeting the cytoplasmic membrane or an enzy-
matic activity targeting peptidoglycan synthesis13,14. Pyocins S1, S2, S3 and AP41 display DNase activity, pyocin 
S4 is a tRNase, pyocin S5 is a pore-forming toxin, pyocin S6 is an rRNase and pyocin M degrades lipid II14,25,26. 
For the recently described lectin-like pyocin L1 the cytotoxic mechanism is unknown. Their potency, targeting 
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of essential nutrient uptake systems and active uptake across the outer membrane makes them ideal antibiotic 
candidates for the treatment of P. aeruginosa infection.
In this work we show that pyocin S2, pyocin AP41, pyocin S5 and pyocin L1 delivered directly to the murine 
lung display strong efficacy against diverse strains of P. aeruginosa in a murine model of acute P. aeruginosa lung 
infection. Furthermore, pyocin S5 is several orders of magnitude more potent than tobramycin and also offers 
protection against a lethal P. aeruginosa infection in the presence of pyocin S5-specific antibodies.
Results
Pyocins are stable in the murine lung. To determine if pyocins can be effectively delivered to the lungs 
and are stable in this environment, recombinant pyocins S2, S5, AP41 and L1 (75 μ g), were administered intra-
nasally to healthy C57/BL6 mice (n = 3). After a 24 h incubation period, the postcaval lobe was removed from 
treated mice, homogenised and tested for the presence of active pyocin. Killing of P. aeruginosa was detected in 
lung homogenates from pyocin L1, S2 and S5 treated mice. Activity for pyocin AP41 was not detected, which 
could indicate this pyocin may be degraded in vivo (Fig. 1a). To investigate the effects of a single administration 
of pyocin on the host, pyocins S2, S5, AP41 and L1 (75 μ g) were administered intranasally and after 24 h pyocin 
treated lungs were fixed using formalin (n = 4). Lung tissues visualised using hematoxylin and eosin staining were 
then scored for peribronchial infiltrate and alveolar macrophage involvement. The pyocin treated lungs showed 
no evidence of inflammatory infiltrate and were indistinguishable from the PBS treated lungs (Fig. 1b).
Figure 1. Pyocins are stable and do not cause inflammation or tissue damage in the murine lung. (a) Spot 
tests to determine stability of pyocins (75 μ g) in lung tissue (24 h after administration) against P. aeruginosa P8 
(P. aeruginosa P17 for pyocin S2). Five microlitres of homogenised post-caval lobe lung section in 100 μ l of PBS 
was spotted onto a growing lawn of P. aeruginosa. The presence of clear zones indicates pyocin activity in the 
lung tissue and that pyocins are stable and still active in vivo for 24 h. (b) Hematoxylin and eosin (H&E) staining 
of paraffin-embedded sections of pyocin (75 μ g) treated lung. Lack of inflammation or neutrophil influx are 
noted. All magnifications × 10.
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Pyocins can afford protection against lethal P. aeruginosa infections. To determine if pyocins 
are sufficiently active in the lung to reduce bacterial load, pyocins S2, S5, AP41 and L1 (75 μ g) or PBS for control 
mice, were administered intranasally 1 h post-infection with a normally lethal dose (approx 1 × 107 CFU) of 
P. aeruginosa P8, a non-mucoid aztreonam-resistant isolate from a cystic fibrosis (CF) patient. In these experi-
ments mice were culled at 4.5 h post-infection and bacterial counts from lung homogenates were compared to 
PBS-treated controls. Pyocin S5 showed greatest efficacy in reducing bacterial numbers and viable bacteria were 
recovered from only three out of six pyocin S5 treated mice (Fig. 2a). Pyocins L1, S2, and AP41 significantly 
reduced the bacterial load by approximately 20-, 80- and 130-fold, respectively (Fig. 2a). This experiment was 
repeated and again all pyocin treated groups showed significantly reduced bacterial counts (Figure S1a).
To determine if pyocin treatment affords protection against a lethal P. aeruginosa infection, mice (n = 6) were 
similarly infected with P. aeruginosa P8 and treated 1 h post-infection with pyocins S2, S5, AP41 and pyocin L1 
(75 μ g). All PBS-treated mice were culled at 4.5 h post-infection and all pyocin treated mice survived to the end-
point of the experiment at 24 h. In this experiment, pyocin S5 again showed the greatest efficacy with no bacteria 
recovered from any of the six pyocin S5 treated mice. In addition, pyocins S2, L1 and AP41 were also highly 
effective in this model significantly reducing bacterial counts in excess of 4-log units (Fig. 2b). This experiment 
was repeated, all pyocin treated mice survived to 24 h and bacterial counts were similarly significantly reduced 
(Figure S1b). Thus, pyocins are highly effective in reducing bacterial load in the lung and are able to afford protec-
tion against a lethal P. aeruginosa infection when administered post-infection. In similar experiments in which 
mice were pre-treated with pyocin 6 h prior to infection, pyocins were shown to be similarly effective in reducing 
bacterial numbers and in protecting against a normally lethal P. aeruginosa infection (Figure S2a,b).
Since strains of P. aeruginosa are phenotypically diverse, we tested the efficacy of the pyocins against three 
additional isolates. Including P. aeruginosa P8 the phenotypes covered, using the minimal number of strains so 
as to reduce animal numbers, were mucoid, non-mucoid, drug-resistant, environmental and clinical: P. aerugi-
nosa P17 and P. aeruginosa P5 (mucoid), both from CF patients and P. aeruginosa E2, an environmental isolate. 
Pyocin S2 was not active against P. aeruginosa P5 or P. aeruginosa E2 in vitro, therefore was not used to treat 
these strains in vivo and similarly pyocin L1 was not used against P. aeruginosa P17. Pyocin S5, L1 and S2 treated 
mice infected with P. aeruginosa P17, P5 or E2 all survived until the endpoint of the experiment (24 h) and viable 
bacteria counts were either reduced to low levels or absent (Table S1). In contrast, treatment of P. aeruginosa E2 
with pyocin AP41 failed to afford protection and these mice were culled at 5.5 h post-infection. However, pyocin 
AP41 treatment was successful for P. aeruginosa P5 infected mice and for five out of six of the P. aeruginosa P17 
infected mice. Thus, pyocins show strong efficacy against diverse strains of P. aeruginosa with pyocin S5 treatment 
displaying the largest effect on reducing bacterial load.
Pyocin tolerance and mitigation strategies. To determine if pyocin tolerance or resistance was 
acquired upon pyocin treatment in vivo, viable bacteria recovered from mice that survived infection to the 24 h 
end-point, in all acute infection experiments discussed in this work, were tested for pyocin susceptibility. From 
these experiments no pyocin resistant colonies were isolated. However, we obtained a single isolate (P8AP41T) 
from a pyocin AP41 treated mouse that showed increased tolerance (approximately 1000-fold) to pyocin AP41. 
The sensitivity of P8AP41T to pyocins S5 and L1 was similar to the parent strain P8 (Fig. 3a). In vivo mice (n = 6) 
infected with P8AP41T and treated with pyocins L1, S2, S5 and AP41 survived until the endpoint of the exper-
iment at 24 h and bacterial numbers were significantly reduced from lung homogenates relative to PBS-treated 
controls, which were culled at 6 h post-infection (Fig. 3b). Thus, a pyocin AP41-tolerant mutant can still be suc-
cessfully treated with pyocin AP41 at high concentrations despite pyocin susceptibility testing showing that this 
strain remained tolerant to pyocin AP41 during infection (Fig. 3a).
As all four pyocins used in this study parasitise different receptors in P. aeruginosa an obvious strategy to 
prevent the occurrence of pyocin resistance is to use ‘pyocin cocktails’ consisting of two or more pyocins in com-
bination. The following pyocin combinations were tested: L1/S2, L1/AP41, S2/AP41 and L1/S2/AP41 with 7.5 μ g 
Figure 2. P. aeruginosa P8 bacterial recovery from pyocin treated mice. All mice were given 75 μ g of pyocin. 
Bacterial counts were determined by CFU counts of homogenised lungs. (a) Mice treated with pyocin 1 h 
post-infection, all mice culled 4.5 h post-infection. (b) Mice treated with pyocin 1 h post-infection, pyocin 
treated mice survived to 24 h. No colonies were recovered from pyocin S5 treated mice in (b). Bars represent 
Mean ± SEM. * Denotes statistical significance for comparison of treatment versus control by a one-sided 
Mann-Whitney U test with Bonferroni correction applied.
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of each pyocin. PBS control mice were culled 4.5 h post-infection and all pyocin treated mice survived until 24 h. 
Viable bacteria were recovered at a low level from pyocin treated mice and for the combination of L1/S2/AP41, 
bacteria were recovered from only one of six treated mice, indicating that pyocin combinations show enhanced 
efficacy over the use of individual pyocins (Fig. 3c).
Pyocin S5 shows improved killing of P. aeruginosa in the murine lung compared to tobramy-
cin. To compare pyocin efficacy directly with a current frontline treatment, we compared pyocin S5 with tobra-
mycin, which is the most commonly used inhaled treatment for P. aeruginosa lung infection in patients with CF. 
To determine the relative potency of pyocin S5 compared to tobramycin, P. aeruginosa P8 infected mice (n = 6) 
were treated with pyocin S5 (750 pg or 7.5 pg) or tobramycin (7.5 μ g or 75 ng). Groups treated with 750 pg of 
pyocin and 7.5 μ g of tobramycin survived to 24 h and had significantly reduced bacterial counts compared to the 
PBS controls (Fig. 4). All other groups were culled 5.5 h post-infection due to the severity of the infection. These 
results show that the lowest dose tested at which pyocin S5 is effective was 750 pg and the lowest dose tested at 
which tobramycin is effective was 7.5 μ g. Therefore, pyocin S5 is between 100-fold and 1,000,000-fold more potent 
than tobramycin in this model of infection.
After ascertaining that pyocin S5 is effective in this model at a concentration lower than 1 nM, we tested the 
efficacy of pyocins S2, L1 and AP41 at lower concentrations than previously used (7.5 μ g and 750 ng). Against 
P. aeruginosa P8, the minimum effective dose of pyocins S2 and AP41 is ≤ 750 ng and the minimum effective dose 
of pyocin L1 is between 7.5 μ g and 750 ng (Table S2).
Figure 3. Acquired tolerance to pyocins can be overcome by treating with a range of pyocins. (a) Activity 
of pyocins S5, AP41 and L1 against WT P8, P8AP41T (a pyocin AP41 tolerant P8 strain) and P8AP41T* 
(P8AP41T recovered from untreated control mice shown in b). Purified protein at 200 μ g ml−1 was spotted onto 
a growing lawn of bacteria. Clear zones indicate pyocin cytotoxicity. (b) Bacterial counts for mice infected with 
P8AP41T and treated 1 h post-infection with pyocins (75 μ g). Pyocin treated mice survived to 24 h. No colonies 
were recovered from pyocin S5 treated mice. Bars represent Mean ± SEM. * Denotes statistical significance 
for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction 
applied. (c) P8 infected mice treated 1 h post-infection with pyocin combinations (7.5 μ g of each pyocin); pyocin 
treated mice survived to 24 h. Bacterial counts were determined by CFU counts from homogenised lungs. Bars 
represent Mean ± SEM. * Denotes statistical significance for comparison of treatment versus control by a one-
sided Mann-Whitney U test with Bonferroni correction applied.
Figure 4. Comparison of pyocin S5 and tobramycin efficacy. Bacterial counts were determined by CFU 
counts of homogenised lungs. (a) Mice treated 1 h post-infection, S5–750 pg and tobramycin–7.5 μ g mice 
survived to 24 h. All other mice culled 5.5 h post-infection. Bars represent Mean ± SEM. * Denotes statistical 
significance for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni 
correction applied.
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Pyocin S5 can afford protection against lethal P. aeruginosa infections in the presence of pyo-
cin S5 antibodies. To ascertain if repeated exposure to pyocins gives rise to an antibody response that is 
detrimental to treatment, mice were repeatedly exposed to high doses (75 μ g) of pyocin S5 (100,000 times the 
effective therapeutic dose of pyocin S5 in this model). Pyocin S5 was administered three times, with two weeks 
between each administration, either via the intranasal route (I.N.) or the intraperitoneal (I.P.) route. Thirteen 
weeks after the first treatment, mice (n = 5) were infected intranasally with P. aeruginosa P8 (I.N. group infected 
with 1.4 × 107 CFU; I.P. group infected with 5.0 × 106 CFU) and treated intranasally 1 h post-infection with 75 μ g 
of pyocin S5 or PBS. A control group administered only PBS, intranasally prior to infection was also included.
For the I.N. groups, all pyocin S5 treated mice survived to the 24 h time-point, while all PBS-treated mice 
were culled 5 h post-infection due to severity of symptoms. The bacterial load of the lungs was determined and no 
viable bacteria were recovered from any of the pyocin S5 treated mice (Fig. 5a). The levels of pyocin-S5 specific 
IgG and IgA were analysed for each mouse. There were no pyocin S5-specific IgA antibodies detected in these 
mice however, there were low levels of pyocin S5-specific IgG present in the mice previously exposed to pyocin 
S5 (10-fold less than that observed in control animals which were immunized with pyocin S5 using Freunds com-
plete/incomplete adjuvant) (Fig. 5b).
All mice exposed to pyocin S5 via the I.P. route and whose infection was subsequently treated with pyocin 
S5 survived to the 24 h time-point. In contrast, animals exposed to pyocin S5 parenterally whose infection was 
Figure 5. Pyocin S5 can afford protection against lethal P. aeruginosa infections in the presence of pyocin 
S5 antibodies. (a) Bacterial counts were determined by CFU counts from homogenised lungs. Multiple doses 
of pyocin S5 (75 μ g/dose) were administered intranasally three times, two weeks apart over four weeks. At 
thirteen weeks, mice were infected with P. aeruginosa P8 and treated with pyocin S5 (75 μ g) or PBS intranasally 
1 h post-infection. Bars represent Mean ± SEM of counts from 5 animals. * Denotes statistical significance 
for comparison of treatment versus control by a one-sided Mann-Whitney U test with Bonferroni correction 
applied. (b) Pyocin S5-specific IgG and IgA serum levels for mice repeatedly exposed to pyocin S5 or PBS 
(as described in a). The control group were immunized subcutaneously (S.C.) with pyocin S5 (75 ug/dose) in 
Freunds complete/incomplete adjuvant on three occasions, two weeks apart. No pyocin S5-specific IgA was 
detected in any of the animals tested. Bars represent Mean ± SEM calculated from the serum of 5 animals per 
group. (c,d) as for (a,b) except mice were repeatedly exposed to pyocin S5 via the intraperitoneal (I.P.) route 
prior to intranasal pyocin S5 or PBS treatment. The pyocin S5-specific IgG levels in (d) were very low in the 
pyocin S5 only group (1000-fold less than the Freunds complete/incomplete control group) and no pyocin S5-
specific IgA was detected.
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treated with PBS were culled 5 h post-infection due to the severity of symptoms. As described above, no viable 
bacteria were recovered from the lungs of pyocin S5 treated mice (Fig. 5c). The pyocin S5-specific IgG levels 
were very low in the pyocin S5 only group (1000-fold less than the Freunds complete/incomplete control group) 
and no pyocin S5-specific IgA was detected (Fig. 5d). Thus, repeated administration of pyocin S5 at 100,000 
times its effective dose either by the I.N. or I.P. routes was very poorly immunogenic, with only small amounts 
of pyocin-specific IgG being produced. Moreover, even in the presence of these low levels of antibody, pyocin S5 
remained highly effective in treating bacterial infection.
Discussion
The development of bacteriocins as novel therapeutics for the treatment of problematic Gram-negative bacteria 
has been widely discussed over the last decade14,27–31. In this work, several different P. aeruginosa–specific pyocins 
were highly effective at reducing bacterial load and affording protection in a lethal P. aeruginosa model of acute 
pneumonia when delivered directly to the murine lung. Pyocins remained stable and retained activity for a mini-
mum of 24 h in this location. Moreover, pyocin-specific antibody production did not appear to affect the efficacy 
of the aforementioned pyocin.
In addition to their potency, the species-specificity of these antibiotics is a desirable trait for two reasons. 
Firstly, unlike broad-spectrum antibiotics, the lack of selective pressure will limit the development of antibiotic 
resistance within the microbial population and secondly, the narrow spectrum of killing provides opportunities 
to successfully treat bacterial infections whilst leaving the normal bacterial flora intact. Well-established com-
plications associated with antibiotic induced dysbiosis include antibiotic-associated diarrhea and Clostridium 
difficile infection32,33. More recently, microbial imbalances have been suggested to play a role in a range of chronic 
diseases such as Crohn’s disease, diabetes, obesity and rheumatoid arthritis34–37. The ability to maintain a healthy 
gut while undergoing antibiotic treatment may not only improve the health of patients, but also the outcome of 
treatment.
Of the pyocins evaluated in this study, the receptors for pyocins S2 and S5 are known to be the TonB-dependent 
iron-siderophore receptors FpvAI and FptA16,17, respectively, whilst pyocin L1 has been shown to bind the com-
mon polysaccharide antigen (CPA) of P. aeruginosa lipopolysaccharide22. The receptor for pyocin AP41 remains 
to be identified. FptA and the CPA are known to be widely distributed among strains of P. aeruginosa23,24,38,39 
and the detection of pyoverdine in the sputa of CF patients suggests that pyoverdine and its receptors FpvAI and 
FpvAII, play a key role in the infection process in humans40,41.
Over the last decade pharmaceutical companies have focused on a post-genomic, target driven antibiotic 
discovery program, with little success and very few small molecule antibiotics making it to market. Most small 
molecule antibiotics currently used in clinical practice came from the identification and modification of naturally 
occurring antibiotics. Therefore, returning to the exploitation of natural products is likely to be a more successful 
route to developing novel antimicrobials.
Methods
Cloning and purification of pyocins. The genes encoding pyocin AP41 and its immunity protein 
(ImAP41) were amplified from the genomic DNA of P. aeruginosa C763 by PCR using primers designed to intro-
duce an NdeI site at the start of the pyocin encoding gene and an XhoI in place of the stop codon of the ImAP41 
encoding gene. The PCR product was digested with NdeI and XhoI and ligated into the corresponding sites of the 
E. coli expression vector pET21a to give pETPyoAP41, which encodes pyocin AP41-ImAP41 with a C-terminal 
His6-tag on the immunity protein. The gene encoding pyocin S5 was similarly amplified from the genomic DNA 
of strain PAO1 and the digested PCR product ligated into pET15b to give pETPyoS5, which encodes pyocin S5 
with an N-terminal His6-tag. Pyocins AP41 and S5 were overexpressed from E. coli BL21(DE3)pLysS carrying 
the relevant plasmid with initial purification by nickel affinity chromatography. Remaining contaminants were 
removed by gel filtration chromatography on a Superdex S200 26/60 column (GE Healthcare). Pyocin L1 and 
the pyocin S2-ImS2 complex were purified as described previously22,27. Contaminating lipopolysaccharide was 
removed using 1 ml gravity flow endotoxin removal columns (Thermo Scientific) and proteins were filter steri-
lised using a 0.2 μ M syringe filter.
Pyocin sensitivity assays. One hundred and fifty microlitres of test strain culture at OD600 = 0.6 was added 
to 6 ml of 0.8% agar and poured over an LB agar plate. Five microlitres of each bacteriocin or lung homogenate at 
varying concentrations was spotted onto the plates and incubated for 24 h at 37 °C.
Ethics statement. All animal experiments were performed in accordance with the UK Animals (Scientific 
procedures) Act, authorized under a UK Home Office License and all procedures were approved by the animal 
project review committee of the University of Glasgow. The project license number assigned by the animal project 
review committee of the University of Glasgow was 60/4361.
In vivo pyocin efficacy. For all experiments, six week-old, female, pathogen-free C57/BL6 mice weigh-
ing 15–21 g were used (Charles Rivers Laboratories, UK). All animals received food and water ad libitum and 
experimental group sizes were calculated from preliminary experiments (data not shown), which indicated that 
statistical significance could be determined using groups of 3 to 6 animals. Experimental endpoints were deter-
mined by a clinical scoring system (based on a number of physical and behavioral attributes) or culled at the 
pre-determined 24 h time point. All mice were culled by carbon dioxide asphyxiation. For intranasal delivery, 
animals were lightly anesthetized using isofluorothane. Mice were inoculated intranasally with 25 μ l of bacterial 
culture containing approximately 1 × 107 CFU of the selected P. aeruginosa strain and/or 25 μ l of pyocin/tobra-
mycin by direct application of the solution to both nostrils (12.5 μ l per nare). The dose of pyocin/tobramycin used 
was based on mg/kg of the antibiotics in a 25 g mouse.
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Histology. Lungs were fixed in situ using 10% formalin solution before being removed and placed in fixative. 
Histology processing and hematoxylin and eosin (H&E) staining was carried out by the Veterinary Diagnostic 
Services Laboratory at the University of Glasgow. High-resolution whole slide images were captured on the Leica 
SCN400 slide scanner and slides were scored blind by two independent assessors for peribronchial infiltrate and 
alveolar involvement.
Repeated pyocin exposure. Pyocin S5 or PBS was given three times, two weeks apart with administration 
either via intranasal route (referred to as I.N. groups) or intraperitoneal route (referred to as I.P. groups). For I.N. 
administration the groups were: PBS and pyocin S5 (75 μ g; 25 μ l at 3 mg ml−1). For I.P. administration the group 
was pyocin S5 (75 μ g; 100 μ l at 750 μ g ml−1). Thirteen weeks after the first exposure mice (n = 5) were infected 
with P. aeruginosa P8 (I.N group infected with 1.4 × 107 CFU, I.P group infected with 5.0 × 106 CFU) and treated 
intranasally one hour post-infection with 75 μ g of pyocin S5 or PBS, as described previously. For analysis of IgG 
and IgA responses, blood was obtained via cardiac puncture immediately after carbon dioxide asphyxiation. 
Serum was stored at − 80 °C. For ELISAs Greiner 96-well plates (MaxiSorp) were coated with purified recombi-
nant pyocin S5 (7.5 μ g ml−1, 50 μ l/well) protein in PBS overnight at 4 °C. The plates were washed three times with 
phosphate buffered saline + 0.05% TWEEN20 (PBST) and then blocked for 1 h at 37 °C with 150 μ l of blocking 
buffer (1% bovine serum albumin (BSA) in PBS). After washing, five-fold serially diluted samples were added, 
starting at a dilution of 1/50 in blocking buffer, and incubated for 2 h at 37 °C. Serum from mice given pyocin 
S5 + Freunds complete/incomplete subcutaneously three times over four weeks was used as a positive control on 
each plate. After washing with PBST, 50 μ l of anti-mouse IgG (Fc specific)–peroxidase antibody ((1/1000 dilu-
tion) Sigma, UK) or anti-mouse IgA (α -chain specific)− peroxidase antibody ((1/250 dilution) Sigma, UK) in 
PBST/0.1%, BSA was added and plates were incubated for 1 h at 37 °C. Plates were developed using SIGMAFAST 
OPD (o-Phenylenediamine dihydrochloride) tablets (Sigma, UK).
Statistics. Due to small sample sizes non-parametric tests were used for analysis. The Kruskal-Wallis 
one-way analysis of variance method was used to test if samples originated from the same distribution. One-sided 
Mann-Whitney U tests with a significance threshold of P ≤ 0.05, adjusted for multiple comparisons using the 
Bonferroni correction, was then used to analyse the specific sample pairs for significant differences. All mice, 
including outliers were included in the statistical analysis.
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